Evaluating only Cempra’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Founded in Chapel Hill, NC, to develop next-generation macrolide antibiotics for respiratory infections.
FUNDING
Raised $185M in follow-on offering to fund Phase 3 trials of solithromycin for community-acquired pneumonia.
REGULATORY ACTION
FDA advisory panel voted 7-3 against solithromycin approval citing liver toxicity risk; stock fell 70%.
FIRE SALE
Cempra merged into Melinta Therapeutics in a distressed deal valued at roughly $270M, ending independence.
Full Analysis
Free · no account needed
Documented cause
Cempra's antibiotic solithromycin (Solithera) received an FDA advisory panel rejection in November 2016 over hepatotoxicity concerns, with the committee voting 7-3 against approval. FDA issued a complete response letter in December 2016. The stock dropped 70% overnight. Unable to fund further studies, Cempra sold itself to Melinta Therapeutics in a distressed merger worth approximately $270M in 2017.
Lesson
“Hepatotoxicity signals in clinical data will sink even promising antibiotics at FDA advisory panels.”